Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Bhanumati Ramineni"'
Autor:
Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James V. Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Publikováno v:
Clinical Cancer Research. 29:1412-1422
Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::099b140efab4ae35818a5a0c4c867b08
https://doi.org/10.1158/1078-0432.ccr-22-3334
https://doi.org/10.1158/1078-0432.ccr-22-3334
Autor:
Jeffrey A. Moscow, Lyndsay N. Harris, James H. Doroshow, Jordan Berlin, Timothy A. Yap, Petros Grivas, Keith T. Flaherty, Bhanumati Ramineni, Douglas S. Hawkins, Robert J. Gray, Stanley R. Hamilton, David Patton, James V. Tricoli, Gary H. Lyman, Julia Glade-Bender, Suzanne George, Roisin E. O'Cearbhaill, Boris Freidlin, Lisa M. McShane, Geoffrey I. Shapiro, Peter J. O'Dwyer, James M. Ford, Funda Meric-Bernstam
Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95ce7ea2922f53625334065386b4e22
https://doi.org/10.1158/1078-0432.c.6533210
https://doi.org/10.1158/1078-0432.c.6533210
Autor:
Jeffrey A. Moscow, Lyndsay N. Harris, James H. Doroshow, Jordan Berlin, Timothy A. Yap, Petros Grivas, Keith T. Flaherty, Bhanumati Ramineni, Douglas S. Hawkins, Robert J. Gray, Stanley R. Hamilton, David Patton, James V. Tricoli, Gary H. Lyman, Julia Glade-Bender, Suzanne George, Roisin E. O'Cearbhaill, Boris Freidlin, Lisa M. McShane, Geoffrey I. Shapiro, Peter J. O'Dwyer, James M. Ford, Funda Meric-Bernstam
supplementary table TS1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11429ff581ea4e4e6669e078777ce535
https://doi.org/10.1158/1078-0432.22633057.v1
https://doi.org/10.1158/1078-0432.22633057.v1
Autor:
Bhanumati Ramineni, R. Rita Misra
In the United States, Federal law requires that a drug or biologic product be the subject of an approved marketing application before it is transported across state lines. Before the sponsor (the individual or entity that is responsible) for the clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2cf18514c10f294d4c16b58c87e73a5e
https://doi.org/10.1016/b978-0-12-812512-0.00002-6
https://doi.org/10.1016/b978-0-12-812512-0.00002-6
Autor:
Pedro C. Barata, Lucia Baratto, Brian Booth, Jessica S. Brown, Alice P. Chen, Johann S. De Bono, Khanh Do, James H. Doroshow, Katherine V. Ferry-Galow, Terry J. Fry, Sanjiv S. Gambhir, Elizabeth Garrett-Mayer, Lacey Greene, Bahru A. Habtemariam, Negin Hatami, David Hong, Susan P. Ivy, John Janik, Patricia Keegan, Samir N. Khleif, Hahn Khuu, Shivaani Kummar, Joline S.J. Lim, Lian Ma, Nitin Mehrotra, Lori M. Minasian, R. Rita Misra, Sandra A. Mitchell, Abhilasha Nair, Tomomi Nobashi, Nathaniel O'Connell, Olanrewaju O. Okusanya, Christy Osgood, Lee Pai-Scherf, Ralph E. Parchment, Sonya Park, Bhanumati Ramineni, Houssein A. Sater, Nirali N. Shah, Haneen Shalabi, Shyam Srinivas, Diane C. St. Germain, Chris H. Takimoto, Marc R. Theoret, Akira Toriihara, Timothy A. Yap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7af9d6e97502b92517adfd0e04cb61a0
https://doi.org/10.1016/b978-0-12-812512-0.00021-x
https://doi.org/10.1016/b978-0-12-812512-0.00021-x
Autor:
Jetsumon Sattabonkot, Dari F. Da, Michael P. Fay, Anna Cohuet, Jianbing Mu, Luc Abate, Yimin Wu, Xin-zhuan Su, Jean-Bosco Ouédraogo, Bhanumati Ramineni, Saurabh Dixit, Nicholas J. MacDonald
Publikováno v:
Infection and Immunity
Infection and Immunity; Vol 81
Infection and Immunity; Vol 81
Pfs25 is a leading candidate for a malaria transmission-blocking vaccine whose potential has been demonstrated in a phase 1 trial with recombinant Pfs25 formulated with Montanide ISA51. Because of limited sequence polymorphism, the anti-Pfs25 antibod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e151b19fbdd13044a11ab3a1bd76efe
https://europepmc.org/articles/PMC3676035/
https://europepmc.org/articles/PMC3676035/